We thank the editors for the opportunity to respond to the comment made by Balkau et al. ([@B1]) on our recent article ([@B2]).

Balkau et al. ([@B1]) were interested in detailed information about HbA~1c~ in the overall group stratified by registry. As stated in the text, HbA~1c~ was similar between the two registries. In the T1D Exchange Registry (TIDX), HbA~1c~ was 8.6% (SE 0.06) in current smokers, 8.0% (0.05) in former smokers, and 7.9% (0.05) in never-smokers (*P* \< 0.001). In the Prospective Diabetes Follow-up Registry (DPV), HbA~1c~ was 8.5% (0.07) in current smokers, 8.2% (0.08) in former smokers, and 7.8% (0.06) in never-smokers (*P* \< 0.001). The findings by Soulimane et al. ([@B3]) in a population without diabetes are of interest to the field as we try to better understand the best markers of glycemia. However, HbA~1c~ is currently the best standardized and internationally comparable measurement of metabolic control in patients with diabetes. Our data describe significant differences in mean HbA~1c~ between current smokers and never-smokers (8.5% and 7.9%, respectively, or a difference of 0.6%) in patients with type 1 diabetes versus a 0.1% difference in subjects who were not treated with glucose-lowering agents, as reported in the meta-analysis by Soulimane et al. ([@B3]). Further studies are required to investigate mechanistic explanations of whether this difference is due to nicotine, red blood cell turnover, or other physiological factors or to smoking-associated behavioral influences on metabolic control. The observation of significantly higher HbA~1c~ levels in smokers is itself of concern. Data from a T1DX study investigating whether a racial difference exists in the relationship between continuous glucose monitoring glucose over 3 months and HbA~1c~ were presented at the 2016 American Diabetes Association Scientific Sessions ([@B4]).
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